Compare Mesoblast Limited (MESO) vs Rush Street Interactive Inc (RSI) Price & Performance

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Rush Street Interactive (RSI) trades at $25.08, up 1.46% today, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Despite a high P/E ratio of 81.13, profitability metrics like a 20.72% ROE and recent earnings beats signal operational strength. Key resistance sits at $26, with support near $24.

The outlook is positive driven by revenue growth and market expansion, but high valuation and mixed technicals pose risks. Analyst consensus is bullish with a $34.75 price target, though regulatory pressures in the gaming sector remain a concern. The stock offers growth potential but requires monitoring of execution and market sentiment.